ACE2 and COVID-19: The most likely reasons for the higher risk of severe clinical course of COVID-19 in COPD patients could be due to the increased protein levels of the SARS-CoV-2 receptor, namely angiotensin converting enzyme-2 (ACE-2) in the lower respiratory tract.